Your browser doesn't support javascript.
loading
Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome.
Engel, Marion; Endesfelder, David; Schloter-Hai, Brigitte; Kublik, Susanne; Granitsiotis, Michael S; Boschetto, Piera; Stendardo, Mariarita; Barta, Imre; Dome, Balazs; Deleuze, Jean-François; Boland, Anne; Müller-Quernheim, Joachim; Prasse, Antje; Welte, Tobias; Hohlfeld, Jens; Subramanian, Deepak; Parr, David; Gut, Ivo Glynne; Greulich, Timm; Koczulla, Andreas Rembert; Nowinski, Adam; Gorecka, Dorota; Singh, Dave; Gupta, Sumit; Brightling, Christopher E; Hoffmann, Harald; Frankenberger, Marion; Hofer, Thomas P; Burggraf, Dorothe; Heiss-Neumann, Marion; Ziegler-Heitbrock, Loems; Schloter, Michael; Zu Castell, Wolfgang.
Afiliação
  • Engel M; Scientific Computing Research Unit, Institute of Computational Biology, Helmholtz Zentrum München, Neuherberg, Germany.
  • Endesfelder D; Research Unit Comparative Microbiome Analysis, Helmholtz Zentrum München, Neuherberg, Germany.
  • Schloter-Hai B; Scientific Computing Research Unit, Institute of Computational Biology, Helmholtz Zentrum München, Neuherberg, Germany.
  • Kublik S; Research Unit Comparative Microbiome Analysis, Helmholtz Zentrum München, Neuherberg, Germany.
  • Granitsiotis MS; Research Unit Comparative Microbiome Analysis, Helmholtz Zentrum München, Neuherberg, Germany.
  • Boschetto P; Research Unit Comparative Microbiome Analysis, Helmholtz Zentrum München, Neuherberg, Germany.
  • Stendardo M; Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
  • Barta I; Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
  • Dome B; Department of Pathophysiology, National Koranyi Institute for TB and Pulmonology, Budapest, Hungary.
  • Deleuze JF; Department of Pathophysiology, National Koranyi Institute for TB and Pulmonology, Budapest, Hungary.
  • Boland A; Centre National de Génotypage, Institut de Génomique, CEA, Evry, France.
  • Müller-Quernheim J; Centre National de Génotypage, Institut de Génomique, CEA, Evry, France.
  • Prasse A; Department of Pneumology, University Medical Center, Freiburg, Germany.
  • Welte T; Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
  • Hohlfeld J; Member of the German Center for Lung Research (DZL), Giessen, Germany.
  • Subramanian D; Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
  • Parr D; Member of the German Center for Lung Research (DZL), Giessen, Germany.
  • Gut IG; Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
  • Greulich T; Member of the German Center for Lung Research (DZL), Giessen, Germany.
  • Koczulla AR; Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany.
  • Nowinski A; Department of Respiratory Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom.
  • Gorecka D; Department of Respiratory Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom.
  • Singh D; CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute for Science and Technology, Barcelona, Spain.
  • Gupta S; Member of the German Center for Lung Research (DZL), Giessen, Germany.
  • Brightling CE; Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg Philipps-University, Marburg, Germany.
  • Hoffmann H; Member of the German Center for Lung Research (DZL), Giessen, Germany.
  • Frankenberger M; Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg Philipps-University, Marburg, Germany.
  • Hofer TP; Second Department of Respiratory Medicine, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland.
  • Burggraf D; Second Department of Respiratory Medicine, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland.
  • Heiss-Neumann M; University of Manchester, Medicines Evaluation Unit and University Hospital of South Manchester Foundation Trust, Manchester, United Kingdom.
  • Ziegler-Heitbrock L; Institute for Lung Health, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom.
  • Schloter M; Institute for Lung Health, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom.
  • Zu Castell W; Institute of Microbiology and Laboratory Medicine, Synlab MVZ Gauting & IML red GmbH, Gauting, Germany.
PLoS One ; 12(7): e0180859, 2017.
Article em En | MEDLINE | ID: mdl-28704452
ABSTRACT

BACKGROUND:

Changes in microbial community composition in the lung of patients suffering from moderate to severe COPD have been well documented. However, knowledge about specific microbiome structures in the human lung associated with CT defined abnormalities is limited.

METHODS:

Bacterial community composition derived from brush samples from lungs of 16 patients suffering from different CT defined subtypes of COPD and 9 healthy subjects was analyzed using a cultivation independent barcoding approach applying 454-pyrosequencing of 16S rRNA gene fragment amplicons.

RESULTS:

We could show that bacterial community composition in patients with changes in CT (either airway or emphysema type changes, designated as severe subtypes) was different from community composition in lungs of patients without visible changes in CT as well as from healthy subjects (designated as mild COPD subtype and control group) (PC1, Padj = 0.002). Higher abundance of Prevotella in samples from patients with mild COPD subtype and from controls and of Streptococcus in the severe subtype cases mainly contributed to the separation of bacterial communities of subjects. No significant effects of treatment with inhaled glucocorticoids on bacterial community composition were detected within COPD cases with and without abnormalities in CT in PCoA. Co-occurrence analysis suggests the presence of networks of co-occurring bacteria. Four communities of positively correlated bacteria were revealed. The microbial communities can clearly be distinguished by their associations with the CT defined disease phenotype.

CONCLUSION:

Our findings indicate that CT detectable structural changes in the lung of COPD patients, which we termed severe subtypes, are associated with alterations in bacterial communities, which may induce further changes in the interaction between microbes and host cells. This might result in a changed interplay with the host immune system.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bactérias / Tomografia Computadorizada por Raios X / Análise de Sequência de DNA / Doença Pulmonar Obstrutiva Crônica / Pulmão Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bactérias / Tomografia Computadorizada por Raios X / Análise de Sequência de DNA / Doença Pulmonar Obstrutiva Crônica / Pulmão Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article